e-learning resources
  • Milan 2017
  • Tuesday, 12.09.2017
  • Login
  • Search all ERS
e-learning resources
  • COVID-19
  • Disease Areas
    • Airways Diseases
    • Interstitial Lung Diseases
    • Respiratory Critical Care
    • Respiratory Infections
    • Paediatric Respiratory Diseases
    • Pulmonary Vascular Diseases
    • Sleep and Breathing Disorders
    • Thoracic Oncology
  • Events
    • International Congress
    • Courses
    • Webinars
    • Conferences
    • Research Seminars
  • Publications
    • Breathe
    • Monograph
    • ERJ
    • ERJ Open Research
    • ERR
    • European Lung White Book
    • Handbook Series
  • Guidelines
    • All ERS guidelines
    • Global Lung Function Initiative
  • e-learning
    • Case reports
    • CME Online
    • SpirXpert
    • Procedure Videos
    • CME tests
    • Reference Database of Respiratory Sounds
    • Radiology Image Challenge
    • Brief tobacco interventions
  • VALUE-Dx
    • Courses and events
  • COVID-19
  • Disease Areas
  • Events
  • Publications
  • Guidelines
  • e-learning
  • VALUE-Dx
  • Login
  • Search

Idiopathic pulmonary fibrosis (IPF): treatment highlights

Oral Presentation
Chairs: A. Wells (London, United Kingdom), K. Antoniou (Heraklion, Crete, Greece)

Download all media Download all media
Extracorporeal membrane oxygenation for the treatment of acute exacerbation of interstitial lung diseases
S. Ohshimo (Hiroshima, Japan)
Congress or journal article abstractWebcastSlide presentation
Congress or journal article abstractWebcastSlide presentation
Late Breaking Abstract - Six years experience of Pirfenidone treatment in IPF patients in Crete: Real life data
K. Karagiannis (Rhodes, Greece)
Congress or journal article abstractWebcastSlide presentation
Congress or journal article abstractWebcastSlide presentation
Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
U. Costabel (Essen, Germany)
Congress or journal article abstractE-poster
Congress or journal article abstractE-poster
PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients
L. Richeldi (Southampton, United Kingdom)
Congress or journal article abstractWebcastSlide presentation
Congress or journal article abstractWebcastSlide presentation
Incidence of multiple progression events in patients with idiopathic pulmonary fibrosis (IPF) in the pooled CAPACITY and ASCEND trials
S. Nathan (Falls Church, United States of America)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON
B. Crestani (Paris, France)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster
Effect of nintedanib on composite physiologic index (CPI) in idiopathic pulmonary fibrosis (IPF)
A. Wells (London, United Kingdom)
Congress or journal article abstractWebcastSlide presentationE-poster
Congress or journal article abstractWebcastSlide presentationE-poster

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.